These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 16552965

  • 1. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
    Ouyang D, Chen FJ, Wei MW, Yang AK, Chen ZQ, Li QL, Chen YF.
    Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
    Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M.
    Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
    [Abstract] [Full Text] [Related]

  • 4. Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
    Matesa N, Samija I, Kusić Z.
    Cytopathology; 2007 Apr; 18(2):112-6. PubMed ID: 17397496
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
    Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, Stern Y.
    Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW.
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
    Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T.
    Cancer; 1999 Jun 01; 85(11):2475-84. PubMed ID: 10357421
    [Abstract] [Full Text] [Related]

  • 11. Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules.
    Hooft L, van der Veldt AA, Hoekstra OS, Boers M, Molthoff CF, van Diest PJ.
    Clin Endocrinol (Oxf); 2008 Feb 01; 68(2):252-7. PubMed ID: 17868400
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Galectin-3 is not useful in thyroid FNA.
    Mills LJ, Poller DN, Yiangou C.
    Cytopathology; 2005 Jun 01; 16(3):132-8. PubMed ID: 15924608
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Galectin-3 in diagnosis of thyroid cancer].
    Semenov DIu, Pozharisskiĭ KM, Boriskova ME, Pankova PA, Mukhina MS, Feshchenko NS.
    Vopr Onkol; 2008 Jun 01; 54(3):321-3. PubMed ID: 18652236
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples.
    Collet JF, Hurbain I, Prengel C, Utzmann O, Scetbon F, Bernaudin JF, Fajac A.
    Br J Cancer; 2005 Nov 14; 93(10):1175-81. PubMed ID: 16251880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.